Darapladib (GSK) fails to meet endpoint in Heart Disease
Top-line results from the Phase III STABILITY trial evaluating darapladib, from Glaxo Smith Kline, in adults with chronic Coronary Heart Disease (CHD) shows the study did not meet the primary endpoint. This measure was time to first occurrence of any major adverse cardiovascular event (MACE) from the composite of myocardial infarction (Heart Attack), Stroke, and cardiovascular Death (relative risk reduction of 6%).
There were greater reductions in some of the pre-defined secondary endpoints that require further analysis. Additional data will be forthcoming from the second Phase III study, SOLID-TIMI 52. Full results of the STABILITY study will be submitted for presentation at a scientific meeting in 2014.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.